stockrowJohnson & Johnson
JNJ Healthcare Drug Manufacturers General
Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024.
- Revenue
- +5.86%
- EPS
- −95.8%
- Free cash flow
- −21.4%
- Total debt
- −9.16%
Quarter to September 2026, against a year earlier
Follow JNJ
Alert me
Johnson & Johnson (JNJ) Current ratio
Johnson & Johnson's current ratio at the end of the quarter to 30 September 2026 was 1.0×, down 0.0× from fiscal 2025 (1.0×). Over the past ten years it has ranged from 1.0× (fiscal 2022) to 2.5× (fiscal 2016); the current reading is higher than 18% of that period. That is below the Drug Manufacturers General industry median of 1.4× and below the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 1.0× | (7.47%) |
| FY2024 | 1.1× | (3.90%) |
| FY2023 | 1.2× | 16.64% |
| FY2022 | 1.0× | (26.51%) |
| FY2021 | 1.3× | 11.82% |
| FY2020 | 1.2× | (4.22%) |
| FY2019 | 1.3× | (14.59%) |
| FY2018 | 1.5× | 4.46% |
| FY2017 | 1.4× | (42.96%) |
| FY2016 | 2.5× | 14.00% |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 1.0× | (6.69%) |
| Jun 2026 | 1.1× | 6.21% |
| Mar 2026 | 1.0× | (0.24%) |
| Dec 2025 | 1.0× | (4.28%) |
| 43 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| AMGN Amgen Inc. compare | 1.5× |
| PFE Pfizer Inc. compare | 1.4× |
| LLY Eli Lilly and Company compare | 1.4× |
| GILD Gilead Sciences, Inc. compare | 1.4× |
| MRK Merck & Co., Inc. compare | 1.3× |
| JNJ Johnson & Johnson | 1.0× |
| AZN AstraZeneca PLC compare | 1.0× |
| NVS Novartis AG compare | 0.9× |
| ABBV AbbVie Inc. compare | 0.9× |
| Drug Manufacturers General industry median | 1.4× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on JNJ
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement